INT194586

From wiki-pain
Revision as of 04:19, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2004
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 2.04
Pain Relevance 2.41

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 255 100.00 Very High Very High Very High
rheumatoid arthritis 389 92.20 High High
methotrexate 251 91.84 High High
Infliximab 134 89.96 High High
headache 5 74.16 Quite High
Arthritis 28 56.20 Quite High
Leflunomide 4 11.28 Low Low
Rheumatism 4 11.12 Low Low
Etanercept 137 5.00 Very Low Very Low Very Low
Inflammation 49 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 396 92.20 High High
Headache 5 74.16 Quite High
Exanthema 2 73.32 Quite High
Disease 165 73.20 Quite High
Rheumatic Diseases 4 11.12 Low Low
INFLAMMATION 52 5.00 Very Low Very Low Very Low
Infection 49 5.00 Very Low Very Low Very Low
Disorder Of Lipid Metabolism 27 5.00 Very Low Very Low Very Low
Necrosis 18 5.00 Very Low Very Low Very Low
Fatigue 18 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Efficacy measures included the proportion of patients who attained an ACR20 response at 24 weeks (primary end point) as well as the proportion of those who met ACR50 and ACR70 response criteria at the end of the study [34].
Negative_regulation (met) of ACR50
1) Confidence 0.26 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.38 Pain Relevance 0.61
Efficacy measures included the proportion of patients who attained an ACR20 response at 24 weeks (primary end point) as well as the proportion of those who met ACR50 and ACR70 response criteria at the end of the study [34].
Negative_regulation (met) of ACR70
2) Confidence 0.26 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.38 Pain Relevance 0.62
At week 52, patients allocated to treatment with tocilizumab achieved an ACR20, ACR50, and ACR70 response of 78%, 64%, and 44% in contrast to 34%, 13%, and 6% in the DMARD group, respectively.
Negative_regulation (achieved) of ACR20
3) Confidence 0.24 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.31 Pain Relevance 0.13
At week 52, patients allocated to treatment with tocilizumab achieved an ACR20, ACR50, and ACR70 response of 78%, 64%, and 44% in contrast to 34%, 13%, and 6% in the DMARD group, respectively.
Negative_regulation (achieved) of ACR70
4) Confidence 0.11 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.31 Pain Relevance 0.13
At week 52, patients allocated to treatment with tocilizumab achieved an ACR20, ACR50, and ACR70 response of 78%, 64%, and 44% in contrast to 34%, 13%, and 6% in the DMARD group, respectively.
Negative_regulation (achieved) of ACR50
5) Confidence 0.11 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.31 Pain Relevance 0.13
The response rate for ACR20 between the adalimumab 20 mg group and placebo at Week 24 was a secondary endpoint and was compared using the Pearson ?
Negative_regulation (compared) of ACR20 associated with adalimumab
6) Confidence 0.09 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2668560 Disease Relevance 0 Pain Relevance 0.17
When we grouped the patients on the basis of their clinical response (ACR improvement criteria) to adalimumab, a significant decrease in RF serum titers was observed in those who were clinically improved according to ACR 20 and ACR 50 at weeks 24 and 48, whereas a decrease was also found for ACR 70 at week 48 (Table 3).
Negative_regulation (improved) of ACR associated with adalimumab
7) Confidence 0.07 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.14 Pain Relevance 0.18
When we grouped the patients on the basis of their clinical response (ACR improvement criteria) to adalimumab, a significant decrease in RF serum titers was observed in those who were clinically improved according to ACR 20 and ACR 50 at weeks 24 and 48, whereas a decrease was also found for ACR 70 at week 48 (Table 3).
Negative_regulation (improved) of ACR associated with adalimumab
8) Confidence 0.07 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.14 Pain Relevance 0.18
A size of 100 patients per group gave 90% power to detect a difference in the primary endpoint (ACR-N) between the 3 and 10 mg/kg groups by use of the two-sided t test at ? 
Negative_regulation (difference) of ACR-N
9) Confidence 0.02 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2759008 Disease Relevance 0.09 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox